Aldeyra's dry eye drug gets a re­jec­tion from the FDA

The FDA hand­ed down a com­plete re­sponse let­ter to Aldeyra Ther­a­peu­tics for its dry eye dis­ease drug re­prox­alap, fol­low­ing months of spec­u­la­tion about whether the drug would be ap­proved.

The com­pa­ny said the agency re­quest­ed an­oth­er clin­i­cal tri­al to in­ves­ti­gate the drug’s ef­fi­ca­cy fur­ther. Aldeyra had pre­vi­ous­ly in­formed in­vestors of that pos­si­bil­i­ty ear­li­er this year and said Mon­day that the pro­posed tri­al is es­ti­mat­ed to cost less than $2 mil­lion, with topline da­ta ex­pect­ed in the first half of next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER